Skip to main content
Premium Trial:

Request an Annual Quote

Schmieg Resigns as CFO of Sirna; Venuti Moves from Celera to Discovery Partners; Evans to be CEO of OGT; Brenner Wins Life Science Achievement Award; and others

Martin Schmieg has resigned as senior vice president and CFO of Sirna Therapeutics for personal and family reasons, effective April 22, the Boulder, Colo-based said last week. He will continue to help the company during a transition period after hiring a new CFO. In the meantime, Patti Ketchner, vice president and corporate controller, will assume Schmieg's responsibilities. Rebecca Galler Robison will take on the company's investor relations function. She is Sirna's senior director of corporate strategy.


 

Michael Venuti has become chief scientific officer of Discovery Partners International, the San Diego-based company said today. He has been a member of Discovery's board of directors since 2003. Venuti joins Discovery from Celera Genomics, where he was senior vice president. He holds a PhD in organic chemistry from the Massachusetts Institute of Technology and an AB in chemistry from DartmouthCollege.


 

Mike Evans will become chief executive officer of Oxford Gene Technology in three months, according to the company. He has also been named director of technical affairs and resource management. He previously held senior administrative positions at Amersham Biosciences and Ascot Fine Chemicals. Evans holds a DPhil, an MA, and a BA in biochemistry from Oxford University.


 

Sydney Brenner has received the 2005 UCSD/Merck Life Sciences Achievement Award, the Universityof California San Diegosaid last week. He is a distinguished professor at the Salk Institute for Biological Studies and a recipient of the 2002 Nobel Prize in medicine, as well as an adjunct professor of biology at UCSD. He received the $25,000 award at a dinner at UCSD on April 1. Brenner was awarded the Nobel Prize for discoveries about how genes regulate organ growth and the process of programmed cell death. He also proved C. elegans to be a useful model organism. In addition, he established the existence of messenger RNA and characterized it further. Brenner holds a DPhil in chemistry from OxfordUniversity and medicine and science degrees from the Universityof Witwatersand in Johannesburg, South Africa.


 

Paul Smith has become vice president of North American and European sales of Ciphergen, the company said on Monday. His appointment is part of the "broad restructuring" of Ciphergen's sales effort.


 

Andrew Chu has become director of business development, and Ian Mehr has been promoted to vice president of business development of Qualyst, the Research Triangle Park, NC-based ADMET company said on Monday. Most recently, Chuwas vice president of business development at Quantum Bio after holding positions at TimeLogic, Accelrys, and Dow Chemical.


 

Gerald Wagner has joined the board of directors of IntregaGen, the Paris-based personalized medicine company said today. During his career, he held senior positions at Agfa and Bayer, retiring from Bayer in 2002. Wagner holds a PhD from the Technical University Darmstadt in Germany.


 

Gary Carter has become vice president of corporate development of CeMines, the Golden, Colo.-based company said yesterday. Most recently, he was responsible for market research at Transgenomic. Prior to that, he was manager of market research at Proligo. Earlier, he held various executive positions at Genomica. Carter holds a master's degree in marketing research from the Universityof Georgia, and a bachelor's degree in business administration from the Universityof South Carolina.


 

Richmond Wolf has become chairman of the advisory board of Arrowhead Research, the company said last week. He is the director of the office of technology transfer at the California Institute of Technology. Wolf received a PhD from Caltech and an undergraduate degree from PrincetonUniversity. Arrowhead is the majority stakeholder in RNAi start-up Calando Pharmaceuticals, which was co-founded by Caltech researcher Mark Davis.


 

Eran Aharonson has become vice president for computational life science research and development of Compugen, the Tel Aviv-based company said on Monday. He joins Compugen from Advanced Recognition Technologies, where he was chief executive officer. Aharonson holds master's and bachelor's degrees in computer science from the Israel Institute of Technology.


 

Philippe Bogard has become strategic marketing manager of Nonlinear Dynamics, the Newcastle upon Tyne, UK-based company said last week. He joins Nonlinear from GE Healthcare, formerly Amersham, where he held various product management positions.


 

Robert Shapiro has joined the board of directors of Dyadic as an independent director, the Jupiter, Fla.-based company said last week. He is the former chairman and chief executive officer of Monsanto and chairman of Pharmacia. Shapiro holds a JD from Columbia University School of Law and a bachelor's degree from HarvardCollege.


 

Staf Van Reet has been appointed as vice president of corporate development of Galapagos, the Belgiumand the Netherlands-based company said last week. He joins Galapagos from Johnson & Johnson where he was vice president of J&J Development. Van Reet holds a PhD in agricultural sciences and a degree in applied biological sciences from the Universityof Leuven in Belgium. He also studied law at the Universityof Antwerpand is a European patent attorney.

 

Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

 

 

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.